AstraZeneca, Bristol diabetes drug disappoints in key test
LONDON (Reuters) - AstraZeneca and Bristol-Myers Squibb's diabetes drug Onglyza failed to reduce heart risks in a large clinical study, disappointing ...
Source: http://feeds.reuters.com/~r/reuters/healthNews/~3/UBQDznfCrEA/story01.htm
No comments:
Post a Comment